Abstract Details

Title ILLUMINATE: Design of a Real-World, Non-Interventional Study Evaluating the Usability and Value of Integrated Digital Solutions for Routine Care of Patients with Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 3-003

Objective

To evaluate the usability and added value of a digital multiple sclerosis (MS) care management platform when introduced in the routine medical care of people with multiple sclerosis (pwMS).

Background

Early initiation of effective disease-modifying therapies is crucial to prevent long-term disease progression in pwMS. To achieve best outcomes for patients an integrated approach is needed. Today, diagnostic tools to assess clinical and subclinical disease activity may be used insufficiently. Therefore, there exists potential to implement technology support-care paths designed to facilitate detection of worsening in disease and to improve interaction between patients and healthcare professionals (HCPs).

Design/Methods ILLUMINATE is a non-interventional study, designed to enroll approximately 500 patients with relapsing MS at 10 sites across 5 countries. The digital MS care management platform under investigation is composed of two certified medical devices: the icompanion MS patient app, to track health and medications and prepare patients for consultations; and icobrain MS, an artificial intelligence solution enabling standardized quantitative analysis of brain MRI data. In addition to retrospective data collection, 2 years of prospective data will be collected focusing on medical practice, as well as treatment, clinical and MRI data on disease worsening and patient-reported outcomes. The primary objective assesses the usability of the MS care management platform via the System Usability Score, reported by HCPs, and the mHealth App Usability Questionnaire, reported by patients. The perceived change in disease state, representing the value provided by the care management platform, will be assessed by semi-structured interviews.

Results

ILLUMINATE will investigate the usability and added valued of a digital MS care management platform for the care of pwMS, with enrollment initiating early 2023.

Conclusions

ILLUMINATE will deliver insights into MS care delivery and the impact of integrated digital tools on the detection of disease worsening.

Authors/Disclosures
Vera Zingler PRESENTER	Vera Zingler has received personal compensation for serving as an employee of Roche. Vera Zingler has stock in Roche.
Tjalf Ziemssen, MD, FAAN (University Clinic Dresden)	Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS . Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Dresden Internation University. The institution of Dr. Ziemssen has received research support from Novartis. The institution of Dr. Ziemssen has received research support from Merck. The institution of Dr. Ziemssen has received research support from Sanofi. The institution of Dr. Ziemssen has received research support from BMS. The institution of Dr. Ziemssen has received research support from Roche.
Petra Dirks	Petra Dirks has received personal compensation for serving as an employee of F. Hoffmann-La Roche Ltd .
	No disclosure on file
	No disclosure on file
Annemie Ribbens	Annemie Ribbens has received personal compensation for serving as an employee of icometrix. Annemie Ribbens has stock in icometrix. Annemie Ribbens has received intellectual property interests from a discovery or technology relating to health care.
Dirk Smeets	Dirk Smeets has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for icometrix. Dirk Smeets has stock in icometrix.
Stephen Krieger, MD, FAAN (Mount Sinai Dept of Neurology)	Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Krieger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Krieger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Krieger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cycle. The institution of Dr. Krieger has received research support from Novartis. The institution of Dr. Krieger has received research support from Bristol Myers Squibb. The institution of Dr. Krieger has received research support from Biogen. The institution of Dr. Krieger has received research support from Sanofi.

��ɫ��

��ɫ��